New Analyst Forecast: $DBVT Given $16.0 Price Target

We just received data on a new analyst forecast for $DBVT. Andrew Fein from H.C. Wainwright set a price target of 16.0 for DBVT.

To track analyst ratings and price targets for $DBVT, check out Quiver Quantitative's $DBVT forecast page.

$DBVT Insider Trading Activity

$DBVT insiders have traded $DBVT stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $DBVT stock by insiders over the last 6 months:

• PHARIS MOHIDEEN (Chief Medical Officer) has made 0 purchases and 4 sales selling 3,857 shares for an estimated $2,282.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$DBVT Hedge Fund Activity

We have seen 5 institutional investors add shares of $DBVT stock to their portfolio, and 5 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• BAKER BROS. ADVISORS LP added 1,461,425 shares (+inf%) to their portfolio in Q4 2024, for an estimated $4,515,803
• BRAIDWELL LP removed 326,108 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,007,673
• UBS GROUP AG added 162,376 shares (+inf%) to their portfolio in Q4 2024, for an estimated $501,741
• MILLENNIUM MANAGEMENT LLC removed 42,743 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $132,075
• NAN FUNG GROUP HOLDINGS LTD added 37,095 shares (+inf%) to their portfolio in Q4 2024, for an estimated $114,623
• POINT72 ASSET MANAGEMENT, L.P. removed 25,000 shares (-8.0%) from their portfolio in Q4 2024, for an estimated $77,250
• MORGAN STANLEY removed 13,762 shares (-23.1%) from their portfolio in Q4 2024, for an estimated $42,524

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.